Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DARA BioSciences has reported the positive results from Phase 1b clinical study of its DB959, a non-TZD oral drug in development to treat type 2 diabetes.
Subscribe to our email newsletter
DB959 is a peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist which activates certain nuclear receptors that regulate the genes involved in controlling blood sugar levels and certain lipids.
The double-blind, escalating multiple dose, placebo-controlled, randomized trial that enrolled 32 healthy male and female volunteers was designed to study the safety and efficacy of DB959.
The results showed that DB959 is safe and well-tolerated and show support for pharmacological activity.
DARA CEO Richard Franco said DB959 is entering Phase 2 with a positive track record from both preclinical and now Phase 1 clinical studies.